NASDAQ OMX

Partners Justin Watts and Matthew Shade Bolster WilmerHale's IP Litigation Practice in London

27.6.2017 17:42 | NASDAQ OMX

Del

LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- WilmerHale today announced that Justin Watts, PhD, and Matthew Shade, PhD, have joined the firm as partners in its London office, strengthening WilmerHale's position as a firm of choice for complex patent litigation in the United Kingdom and for clients seeking an effective global strategy for their intellectual property disputes.

Dr. Watts, a first-chair patent litigator with deep experience in international disputes including competition matters, and Dr. Shade, a skilled practitioner and former patent examiner in the European Patent Office, come to WilmerHale from a Magic Circle firm, where Dr. Watts was the head of the firm's UK IP litigation practice. Together they bring more than 30 years of combined practice, with experience in a wide range of technologies, including cell phones, pharmaceutical products, semiconductors and aero engines."

"Justin and Matthew are an impressive duo who will substantially strengthen our international patent litigation capabilities," said Susan Murley, co-managing partner of WilmerHale. "Their experience with high-stakes IP litigation work and ability to manage complex international patent disputes will benefit our life sciences and tech clients alike."

"The opportunity to join WilmerHale allows us to be a part of a firm that boasts the most esteemed IP litigation practice in the United States," said Dr. Watts. "Matthew and I are looking forward to joining the WilmerHale team and contributing our UK and EU expertise to extend the ways in which clients can rely upon WilmerHale for well-coordinated and comprehensive guidance in global patent litigation matters."

WilmerHale's IP Litigation Practice features a premier litigation team backed by the academic and industry experience of more than 100 lawyers and technology specialists with scientific or technical degrees. WilmerHale's lawyers have tried major cases in US federal district courts from coast to coast, before the US International Trade Commission, and in Germany and the United Kingdom. The firm's lawyers also regularly represent clients in patent appeals before the US Supreme Court and the Federal Circuit. Since the first year the title of IP Litigation Department of the Year was awarded in 2004, The American Lawyer has honored WilmerHale twice and a finalist six times in this biennial contest. 

Mark Selwyn, co-chair of WilmerHale's IP Litigation Practice, added, "It is with great pride that we welcome Justin and Matthew. They bring a superb track record of success and commitment to legal excellence, and they will further enhance our ability to offer clients the finest representation for their global IP litigation disputes." 

Biographical Information

Dr. Justin Watts

Justin Watts, a patent litigator, was most recently a partner in the IP and information technology practices of a Magic Circle firm, where he was the head of the firm's UK IP litigation practice. Dr. Watts has handled complex, multinational disputes, often involving the intersection of antitrust and intellectual property. He has appeared before UK courts and high courts of Northern Ireland and Singapore, and has coordinated international patent litigation in the US, Germany and the Netherlands. His clients span a range of industries from pharmaceutical and medical device to technology, media and communications.

Dr. Watts is a highly regarded practitioner, earning consistent recognition by industry publications such as Chambers UK and The Legal 500 UK, by which he has been cited as "one of the best and most strategic litigators in the field."

Before his legal career began in 1994, Dr. Watts worked in satellite communications engineering. He earned his BA in electrical sciences and his PhD in optoelectronics from the University of Cambridge, and his diploma in IP law and practice, with commendation, from the University of Bristol.

Dr. Matthew Shade

Matthew Shade was most recently a patent litigator at a Magic Circle firm, where he was a member of the firm's intellectual property and information technology practices since 2007. His work focuses on complex multijurisdictional patent cases, and he often deals with the interface of intellectual property and antitrust law. Dr. Shade has practiced before the English courts and the European Patent Office. His clients span industries from pharmaceuticals and medical devices to consumer electronics.

Previously, Dr. Shade managed the patent department of a high-tech spin-out from Cambridge University and he was a patent examiner at the European Patent Office. He earned his BS, with honors, from the University of Manchester, and his PhD in chemistry from the University of Oxford. He is a registered solicitor in England and Wales and a European patent attorney.

About Wilmer Cutler Pickering Hale and Dorr LLP

WilmerHale provides legal representation across a comprehensive range of practice areas that are critical to the success of its clients. The law firm's leading Intellectual Property, Litigation/Controversy, Regulatory and Government Affairs, Securities and Transactional Departments participate in some of the highest-profile legal and policy matters. With a staunch commitment to public service, the firm is renowned as a leader in pro bono representation. WilmerHale is 1,000 lawyers strong with 12 offices in the United States, Europe and Asia. For more information, please visit www.wilmerhale.com.

Lauren C. Bishop
WilmerHale
lauren.bishop@wilmerhale.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: WilmerHale via Globenewswire

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Vistajet Launches New Digital Platforms as Growth Accelerates in China27.7.2017 14:36Pressemelding

VistaJet grows team and launches Chinese website owing to passenger demand VistaJet VistaJet Challenger 850  VistaJet Ltd For the six months to 30th June 2017: Program Membership sales increase globally by a record 57% as customer retention hits 91% across all regions 12% year-on-year increase on passenger departures from China 100% customer renewal rate in Greater China in the first half of 2017 VistaJet Chinese website launched at www.vistajet.cn HONG KONG, July 27, 2017 (GLOBE NEWSWIRE) -- VistaJet continues to build on its China growth and demonstrates a commitment to the region by expanding its team and launching

Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 201727.7.2017 14:30Pressemelding

Management to host conference call WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the second quarter of 2017 on Thursday, August 3, 2017.  The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.  The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 53086270.  A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com.  The archived webcast will be available on the Company's website beginning approximately two hours after

Vertiv Sells ASCO® to Schneider Electric27.7.2017 14:22Pressemelding

Sale enables greater focus on core business COLUMBUS, Ohio, July 27, 2017 (GLOBE NEWSWIRE) -- Vertiv, formerly Emerson Network Power, today announced plans to sell its ASCO® business as it continues to sharpen its focus on the digital critical infrastructure space. The $1.25 billion sale to Schneider Electric allows Vertiv to apply additional resources toward business and technological advancements in its core data center, telecommunications and commercial and industrial markets. As Vertiv has repositioned itself after being sold to Platinum Equity in November 2016, it became clear that ASCO's strengths in the automatic transfer switch arena fell outside the new organization's more focused strategy, said Vertiv CEO Rob Johnson. "This sale is a significant step forward in our evolution as the premier provider of digital critical infrastructure solutions," Johnson said. "This is consistent with our strategy of focus

Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year27.7.2017 13:00Pressemelding

Company announces Japanese reimbursement for Impella® heart pumps and raises lower end of FY 2018 revenue guidance DANVERS, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 revenue of $132.5 million, an increase of 29% compared to revenue of $103.0 million for the same period of fiscal 2017. First quarter fiscal 2018 GAAP net income was $37.4 million or $0.82 per diluted share, compared to GAAP net income of $12.9 million or $0.29 per diluted share for the prior year period.   Financial and operating highlights during the first quarter of fiscal 2018 include: Fiscal first quarter worldwide revenue from Impella® heart pumps totaled $127.2 million, an increase of 30% compared to revenue of $97.8 million during the same period of the prior fiscal year.  U.S. revenue from Impella heart pumps grew 28% to $114.7 million and

TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan27.7.2017 13:00Pressemelding

-   Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia -   TESARO to Receive $100 Million Upfront Payment and is Eligible for Future Regulatory and Commercial Milestones, Plus Royalties WALTHAM, Mass. and OSAKA, Japan, July 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and clinical development of niraparib, a novel poly ADP-ribose polymerase (PARP) inhibitor. This agreement includes the development of niraparib for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. Niraparib, first marketed in the U.S. in April under the brand name ZEJULA(TM), has quickly

Concurrent Introduces Media Delivery Springboard26.7.2017 17:34Pressemelding

Fully Featured Entry Level Video-on-Demand and Live-Streaming Solutions for Cable Operators ATLANTA, July 26, 2017 (GLOBE NEWSWIRE) -- Concurrent (NASDAQ:CCUR), a global leader in storage, protection, transformation and delivery of visual assets, introduces today its new Media Delivery Springboard solutions, a cost-effective means for small and medium-sized independent cable operators to ingest, store, transform and deliver video-on-demand (VOD) and live-streaming content.   Traditional content delivery networks come with high start-up costs, which present a challenge for small and mid-size operators that may lack the necessary capital to invest in large-scale infrastructure. Concurrent's new Media Delivery Springboard helps independent cable operators with smaller budgets and limited resources remain competitive with an entry-level video delivery solution requiring minimal infrastructure investment.    There are three options available, including a VOD solution fo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom